BR112013033919A2 - combinações e seus usos - Google Patents

combinações e seus usos

Info

Publication number: BR112013033919A2
Authority: BR; Brazil
Prior art keywords: combinations
Prior art date: 2011-08-16

Application number

BR112013033919A

Other languages

English (en)

Other versions

BR112013033919B1 (pt

Inventor

Amersdorfer Jutta

Rojkjaer Lisa

Winderlich Mark

Steidl Stefan

Krohn Susanne

Original Assignee

Morphosys Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-16

Filing date

2012-08-14

Publication date

2017-12-19

2012-08-14 Application filed by Morphosys Ag filed Critical Morphosys Ag

2017-12-19 Publication of BR112013033919A2 publication Critical patent/BR112013033919A2/pt

2022-11-16 Publication of BR112013033919B1 publication Critical patent/BR112013033919B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BR112013033919-5A 2011-08-16 2012-08-14 Uso de um anticorpo específico para cd19 BR112013033919B1 (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201161523861P	2011-08-16	2011-08-16
US61/523,861		2011-08-16
EP11177658.9		2011-08-16
EP11177658		2011-08-16
US201261647539P	2012-05-16	2012-05-16
US61/647,539		2012-05-16
US201261654097P	2012-06-01	2012-06-01
US61/654,097		2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en)	2011-08-16	2012-08-14	Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (2)

Publication Number	Publication Date
BR112013033919A2 true BR112013033919A2 (pt)	2017-12-19
BR112013033919B1 BR112013033919B1 (pt)	2022-11-16

Family

ID=47714801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112013033919-5A BR112013033919B1 (pt)	2011-08-16	2012-08-14	Uso de um anticorpo específico para cd19

Country Status (22)

Country	Link
US (2)	US20140255427A1 (pt)
EP (2)	EP2744515B1 (pt)
JP (1)	JP6184952B2 (pt)
KR (3)	KR20200058583A (pt)
CN (1)	CN103732252B (pt)
AU (1)	AU2012296907B2 (pt)
BR (1)	BR112013033919B1 (pt)
CA (2)	CA3137321A1 (pt)
DK (1)	DK2744515T3 (pt)
ES (1)	ES2909722T3 (pt)
HR (1)	HRP20220228T1 (pt)
HU (1)	HUE058350T2 (pt)
IL (1)	IL230293B (pt)
LT (1)	LT2744515T (pt)
MX (1)	MX354479B (pt)
PL (1)	PL2744515T3 (pt)
PT (1)	PT2744515T (pt)
RS (1)	RS63238B1 (pt)
RU (1)	RU2625222C2 (pt)
SG (1)	SG10201606785UA (pt)
SI (1)	SI2744515T1 (pt)
WO (1)	WO2013024097A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106794231A (zh) *	2014-06-16	2017-05-31	赞科股份有限公司	用于慢性淋巴细胞性白血病（cll）的治疗
EP3603672A1 (en) *	2015-05-26	2020-02-05	MorphoSys AG	Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
EP3337506B1 (en)	2015-08-21	2021-07-21	MorphoSys AG	Combinations and uses thereof
EP3436070A4 (en)	2016-03-29	2019-11-27	University of Southern California	CHIMERIC ANTIGENIC RECEPTORS TARGETING CANCER
PT3916392T (pt) *	2016-05-30	2024-06-04	Incyte Corp	Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes
IL301786A (en)	2016-10-28	2023-05-01	Morphosys Ag	Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
BR112019025034A2 (pt)	2017-05-31	2020-06-30	Morphosys Ag	combinação
JP7460333B2 (ja)	2019-06-13	2024-04-02	タキロンシーアイ株式会社	化粧シート及び化粧シートの製造方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4708871A (en)	1983-03-08	1987-11-24	Commonwealth Serum Laboratories Commission	Antigenically active amino acid sequences
US5686072A (en)	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
KR100508289B1 (ko) *	1998-04-21	2005-08-17	마이크로메트 에이지	Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
DE60024436T2 (de) *	1999-05-07	2006-08-17	Genentech, Inc., South San Francisco	Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
MXPA03002262A (es)	2000-09-18	2003-10-15	Idec Pharma Corp	Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
CA2467633C (en)	2001-12-03	2012-03-27	Abgenix, Inc.	Antibody categorization based on binding characteristics
US20080260731A1 (en) *	2002-03-01	2008-10-23	Bernett Matthew J	Optimized antibodies that target cd19
WO2005012493A2 (en)	2003-07-31	2005-02-10	Immunomedics, Inc.	Anti-cd19 antibodies
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
EP1814544A4 (en)	2004-11-05	2009-12-02	Cephalon Inc	CANCER TREATMENTS
CA2611814A1 (en)	2005-06-20	2007-01-04	Medarex, Inc.	Cd19 antibodies and their uses
ATE509954T1 (de) *	2005-12-30	2011-06-15	Merck Patent Gmbh	Anti-cd19-antikörper mit reduzierter immunogenität
EP2059536B1 (en) *	2006-08-14	2014-01-08	Xencor, Inc.	Optimized antibodies that target cd19
CN103694349A (zh)	2006-09-08	2014-04-02	米迪缪尼有限公司	人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
EP2708557A1 (en)	2007-05-30	2014-03-19	Xencor, Inc.	Method and compositions for inhibiting CD32B expressing cells
AU2008311815B2 (en)	2007-10-19	2014-02-06	Seagen Inc.	CD19 binding agents and uses thereof
CA2749151A1 (en) *	2009-01-16	2010-07-22	Glaxosmithkline Llc	Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
MX2011008843A (es)	2009-02-23	2011-12-14	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados que se unen a cd19 y sus usos.
WO2010151341A1 (en)	2009-06-24	2010-12-29	The Feinstein Institute For Medical Research	Method for treating chronic lymphocytic leukemia
TWI409079B (zh) *	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) *	2009-08-14	2011-02-17	Roche Glycart Ag	Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
WO2011057222A1 (en) *	2009-11-06	2011-05-12	Infinity Pharmaceuticals, Inc.	Oral formulations of a hedgehog pathway inhibitor

2012
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko active Application Filing
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active IP Right Grant
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en active Application Filing
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Application Discontinuation
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX354479B (es)	2018-03-07
KR102115203B1 (ko)	2020-05-28
JP2014525926A (ja)	2014-10-02
RU2014103492A (ru)	2015-09-27
EP4062936A1 (en)	2022-09-28
EP2744515A1 (en)	2014-06-25
US20140255427A1 (en)	2014-09-11
RU2625222C2 (ru)	2017-07-12
CA2841875A1 (en)	2013-02-21
JP6184952B2 (ja)	2017-08-23
KR20190107749A (ko)	2019-09-20
MX2013014933A (es)	2014-04-16
KR20140064873A (ko)	2014-05-28
PT2744515T (pt)	2022-05-19
CN103732252B (zh)	2017-11-10
US20200353077A1 (en)	2020-11-12
EP2744515B1 (en)	2022-02-09
CN103732252A (zh)	2014-04-16
NZ617770A (en)	2016-01-29
IL230293B (en)	2019-01-31
WO2013024097A1 (en)	2013-02-21
SI2744515T1 (sl)	2022-05-31
LT2744515T (lt)	2022-04-25
ES2909722T3 (es)	2022-05-10
CA3137321A1 (en)	2013-02-21
DK2744515T3 (da)	2022-03-28
SG10201606785UA (en)	2016-10-28
HRP20220228T1 (hr)	2022-05-13
HUE058350T2 (hu)	2022-07-28
CA2841875C (en)	2021-11-02
PL2744515T3 (pl)	2022-05-30
BR112013033919B1 (pt)	2022-11-16
AU2012296907B2 (en)	2017-01-05
KR20200058583A (ko)	2020-05-27
RS63238B1 (sr)	2022-06-30

Publication	Publication Date	Title
BR112013006272A2 (pt)	2019-09-24	compostos de piridina e seus usos
BR112015014063A2 (pt)	2018-10-30	anticorpos anti-b7-h4 humano e seus usos.
CO7030961A2 (es)	2014-08-21	Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO6821892A2 (es)	2013-12-31	Anticuerpos anti-angptl3 y usos de los mismos
BR112013007499A2 (pt)	2016-07-12	piridazinonas - métodos de criação e usos
BR112014000765A2 (pt)	2017-06-13	agentes de ligação a rspo e seus usos
BR112013012190A2 (pt)	2017-11-07	composições adesivas e seus usos
BR112015006198A2 (pt)	2017-07-04	conjunto de cadeira
BR112013024052A2 (pt)	2016-12-13	artigo absorvente
BR112013029345A2 (pt)	2017-02-07	métodos e aplicações de estabilidade de espuma melhoradas
BR112015004817A2 (pt)	2017-07-04	bioconjugados compreendendo antígenos modificados e seus usos
BR112013033308A2 (pt)	2017-03-07	assento
CO6990717A2 (es)	2014-07-10	Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6870031A2 (es)	2014-02-20	Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
DK3421470T3 (da)	2021-04-06	Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
DK2690985T3 (da)	2021-03-22	Møbel
BR112013026298A2 (pt)	2019-09-24	inibidores de micro-rna e seus usos em doenças
BR112013033919A2 (pt)	2017-12-19	combinações e seus usos
BR112013008898A2 (pt)	2016-06-28	benzamidas substituídas e seus usos
DK3392252T3 (da)	2024-01-08	Pyrimido-pyridazinonforbindelser og deres anvendelse
BR112014000003A2 (pt)	2017-02-07	artigo absorvente
BR112015007217A2 (pt)	2017-08-08	compostos e usos do composto
CO6862154A2 (es)	2014-02-10	Metabolitos de trans-clomifeno y usos de los mismos
BR112013025723A2 (pt)	2017-08-08	elementos absorventes volumosos
CL2013000132S1 (es)	2013-11-04	Silla

Legal Events

Date	Code	Title	Description
2018-03-27	B25G	Requested change of headquarter approved	Owner name: MORPHOSYS AG (DE)
2018-04-03	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2021-09-08	B07G	Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]	Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021
2021-09-21	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2022-05-10	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-09-06	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-11-16	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.